FASLG and systemic lupus erythematosus: <h4>Objective</h4>To characterize the dynamic changes in B-cell subsets in Systemic lupus erythematosus (SLE) patients with antiphospholipid antibody (aPL) positivity treated with telitacicept and to identify baseline predictors of treatment response.<h4>Methods</h4>Twenty patients with active aPL-positive SLE receiving telitacicept in addition to standard therapy were enrolled, and 20 healthy individuals served as controls.